Vermillion ropes in $18.8M for R&D; Cytox and Affymetrix join forces for Alzheimer's Dx;

> Vermillion ($VRML) raised $18.8 million in a public offering to expand its testing portfolio, improve its bioinformatics platform and spur marketing in the U.S. and abroad. Statement

> U.K.-based Cytox and Affymetrix ($AFFX) are teaming up to develop a blood-based genetic test for Alzheimer's disease and mild cognitive impairment. Release

> Inova Diagnostics got an FDA OK for its tests for connective tissue diseases such as lupus and its marker for antiphospholipid syndrome. More

> Thermo Fisher Scientific ($TMO) is rolling out new technology developed with the CDC that allows global public health labs to more quickly identify harmful microbial pathogens. Statement

> Roche ($RHHBY) expanded its HIV Global Access Program to cover early diagnostic testing for infants in low and middle income countries. More

And Finally… A U.K. research firm is developing technology to create new diagnostic tests with an inkjet printer. Story